Common Stock	12 Months Ended
Apr. 30, 2018
Equity [Abstract]
Common Stock	Common Stock On June 15, 2016, the Company closed a public offering ("The June 2016 Public Offering") of 2,000,000 registered shares of its common stock at an offering price of $2.25 per share. In addition, the underwriter exercised a partial exercise of the over-allotment option granted to the underwriter to purchase an additional 258,749 shares of its common stock at the public offering price. All of the shares have been offered by the Company. The net proceeds from The June 2016 Public Offering, including the partial exercise of the over-allotment option, was $4.3 million, after deducting the underwriting discount and offering-related expenses of $742,000. The Company used the net proceeds of this offering for research and development to grow the TumorGraft platform, and the balance of the net proceeds for working capital and general corporate purposes. As of April 30, 2018, the Company issued a total of 8,569 shares of common stock valued at $22,500 in consideration for consulting services. As of April 30, 2017, the Company issued a total of 18,564 share of common stock valued at $43,040 in consideration for consulting services.

Common Stock

On June 15, 2016, the Company closed a public offering ("The June 2016 Public Offering") of 2,000,000 registered shares of its common stock at an offering price of $2.25 per share. In addition, the underwriter exercised a partial exercise of the over-allotment option granted to the underwriter to purchase an additional 258,749 shares of its common stock at the public offering price. All of the shares have been offered by the Company.

The net proceeds from The June 2016 Public Offering, including the partial exercise of the over-allotment option, was $4.3 million, after deducting the underwriting discount and offering-related expenses of $742,000. The Company used the net proceeds of this offering for research and development to grow the TumorGraft platform, and the balance of the net proceeds for working capital and general corporate purposes.

As of April 30, 2018, the Company issued a total of 8,569 shares of common stock valued at $22,500 in consideration for consulting services.

As of April 30, 2017, the Company issued a total of 18,564 share of common stock valued at $43,040 in consideration for consulting services.